Trial Profile
An Exploratory Phase II Study to Demonstrate the Safety and Efficacy of A4250 in Children With Cholestatic Pruritus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Odevixibat (Primary)
- Indications Alagille syndrome; Biliary atresia; Intrahepatic cholestasis; Primary sclerosing cholangitis; Pruritus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Albireo AB
- 07 Jun 2019 According to an Albireo Pharma media release, clinical data from this study were presented at the 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting in Glasgow, Scotland.
- 07 Jun 2019 Results published in the Albireo Pharma Media Release.
- 23 May 2019 According to an Albireo Pharma media release, data from the study will be presented at the 52nd European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting 2019.